Plasmodium vivax: who cares?
- PMID: 19091043
- PMCID: PMC2604873
- DOI: 10.1186/1475-2875-7-S1-S9
Plasmodium vivax: who cares?
Abstract
More attention is being focused on malaria today than any time since the world's last efforts to achieve eradication over 40 years ago. The global community is now discussing strategies aimed at dramatically reducing malarial disease burden and the eventual eradication of all types of malaria, everywhere. As a consequence, Plasmodium vivax, which has long been neglected and mistakenly considered inconsequential, is now entering into the strategic debates taking place on malaria epidemiology and control, drug resistance, pathogenesis and vaccines. Thus, contrary to the past, the malaria research community is becoming more aware and concerned about the widespread spectrum of illness and death caused by up to a couple of hundred million cases of vivax malaria each year. This review brings these issues to light and provides an overview of P. vivax vaccine development, then and now. Progress had been slow, given inherent research challenges and minimal support in the past, but prospects are looking better for making headway in the next few years. P. vivax, known to invade the youngest red blood cells, the reticulocytes, presents a strong challenge towards developing a reliable long-term culture system to facilitate needed research. The P. vivax genome was published recently, and vivax researchers now need to coordinate efforts to discover new vaccine candidates, establish new vaccine approaches, capitalize on non-human primate models for testing, and investigate the unique biological features of P. vivax, including the elusive P. vivax hypnozoites. Comparative studies on both P. falciparum and P. vivax in many areas of research will be essential to eradicate malaria. And to this end, the education and training of future generations of dedicated "malariologists" to advance our knowledge, understanding and the development of new interventions against each of the malaria species infecting humans also will be essential.
Similar articles
-
An update on the search for a Plasmodium vivax vaccine.Trends Parasitol. 2007 Mar;23(3):122-8. doi: 10.1016/j.pt.2007.01.008. Epub 2007 Jan 29. Trends Parasitol. 2007. PMID: 17258937 Review.
-
Platform for Plasmodium vivax vaccine discovery and development.Mem Inst Oswaldo Cruz. 2011 Aug;106 Suppl 1(Suppl 1):179-92. doi: 10.1590/s0074-02762011000900023. Mem Inst Oswaldo Cruz. 2011. PMID: 21881773 Free PMC article. Review.
-
Plasmodium vivax malaria vaccines: why are we where we are?Hum Vaccin Immunother. 2013 Dec;9(12):2558-65. doi: 10.4161/hv.26157. Epub 2013 Aug 26. Hum Vaccin Immunother. 2013. PMID: 23978931 Free PMC article. Review.
-
A Library of Plasmodium vivax Recombinant Merozoite Proteins Reveals New Vaccine Candidates and Protein-Protein Interactions.PLoS Negl Trop Dis. 2015 Dec 23;9(12):e0004264. doi: 10.1371/journal.pntd.0004264. eCollection 2015 Dec. PLoS Negl Trop Dis. 2015. PMID: 26701602 Free PMC article. Clinical Trial.
-
Vaccination for vivax malaria: targeting the invaders.Trends Parasitol. 2004 Mar;20(3):99-102. doi: 10.1016/j.pt.2003.12.003. Trends Parasitol. 2004. PMID: 16676415 Review.
Cited by
-
Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis.Lancet Infect Dis. 2012 Jun;12(6):457-68. doi: 10.1016/S1473-3099(12)70055-5. Epub 2012 Mar 23. Lancet Infect Dis. 2012. PMID: 22445352 Free PMC article. Review.
-
Multiplicity and diversity of Plasmodium vivax infections in a highly endemic region in Papua New Guinea.PLoS Negl Trop Dis. 2011 Dec;5(12):e1424. doi: 10.1371/journal.pntd.0001424. Epub 2011 Dec 20. PLoS Negl Trop Dis. 2011. PMID: 22206027 Free PMC article.
-
B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax merozoite surface protein-3α (PvMSP-3α) in malaria exposed individuals from Brazilian Amazon.Vaccine. 2011 Feb 17;29(9):1801-11. doi: 10.1016/j.vaccine.2010.12.099. Epub 2011 Jan 6. Vaccine. 2011. PMID: 21215342 Free PMC article.
-
Duffy negative antigen is no longer a barrier to Plasmodium vivax--molecular evidences from the African West Coast (Angola and Equatorial Guinea).PLoS Negl Trop Dis. 2011 Jun;5(6):e1192. doi: 10.1371/journal.pntd.0001192. Epub 2011 Jun 21. PLoS Negl Trop Dis. 2011. PMID: 21713024 Free PMC article.
-
The development of loop-mediated isothermal amplification targeting alpha-tubulin DNA for the rapid detection of Plasmodium vivax.Malar J. 2014 Jun 30;13:248. doi: 10.1186/1475-2875-13-248. Malar J. 2014. PMID: 24981710 Free PMC article.
References
-
- World Malaria Report. World Health Organization: WHO Press; 2008.
-
- Baird JK. Neglect of Plasmodium vivax malaria. Trends Parasitol. 2007;23:533–539. - PubMed
-
- AY Lysenko INS. Medical Geography. Medvedkov YV. Moscow; 1968. Geography of malaria: a medical-geographical study of an ancient disease.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous